Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

Last updated: September 27, 2024
Sponsor: Jonsson Comprehensive Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Gliomas

Astrocytoma

Treatment

Magnetic Resonance Imaging

Biospecimen Collection

Medical Chart Review

Clinical Study ID

NCT06090903
21-002112
NCI-2022-03536
R01CA270027
  • Ages > 18
  • All Genders

Study Summary

This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the United States. Glioblastoma is a type of malignant glioma with very poor patient prognosis. There are currently only about 3 drugs approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma, one of them being administration of bevacizumab, which is very expensive. It is the most widely used treatment for glioblastoma with dramatic results. However, previous clinical trials have not demonstrated an overall survival benefit across all patient populations with glioblastoma that has returned after treatment (recurrent). The study aims to identify which patients who will benefit from bevacizumab therapy by observing MRI images and corresponding imaging biomarkers.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients > 18 years of age

  • Patients with newly diagnosed, suspected or recurrent glioblastoma (GBM) patientswith enhancing tumors greater than 1.5 mL clinically indicated for surgicalresection. Recurrent GBM must have occurred more than 3 months after the end ofradiation therapy per Response Assessment in Neuro-Oncology Criteria (RANO)guidelines

Exclusion

Exclusion Criteria:

  • Counterindication to magnetic resonance imaging (MRI) (Patient has a pacemaker ormetal in the body)

  • Patients < 18 years of age

Study Design

Total Participants: 50
Treatment Group(s): 3
Primary Treatment: Magnetic Resonance Imaging
Phase:
Study Start date:
April 14, 2022
Estimated Completion Date:
April 18, 2028

Study Description

PRIMARY OBJECTIVES:

I. Enhancing tumors with high diffusion measurements (low apparent diffusion coefficient [ADCL] > 1.24 um^2/ms) will have higher DCN protein expression compared with tumors exhibiting low diffusion measurements (ADCL < 1.24 um^2/ms.) (Aim 1A) II. Enhancing tumors with high diffusion measurements (low apparent diffusion coefficient [ADCL] > 1.24 um^2/ms) will have higher deoxyribonucleic acid (DNA) expression compared with tumors exhibiting low diffusion measurements (ADCL < 1.24 um^2/ms.) (Aim 1B) III. Enhancing tumors with high diffusion measurements (low apparent diffusion coefficient [ADCL] > 1.24 um^2/ms) will have higher ribonucleic acid (RNA) expression compared with tumors exhibiting low diffusion measurements (ADCL < 1.24 um^2/ms.) (Aim 1C) IV. Mesenchymal-Like (MES-like) cells will have higher frequency of incidence of tumors with high diffusion measurements (ADCL > 1.24 um^2/ms) and higher overall DCN expression levels compared to other genotypes.

SECONDARY OBJECTIVE:

I. DCN immunohistochemistry (IHC), in-situ hybridization (ISH), and RNA expression within the tumor will be linearly correlated with continuous values of diffusion measurements (ADCL).

OUTLINE:

Patients undergo one MRI scan over approximately 1 hour prior to surgery.

Connect with a study center

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California 90095
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.